EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

July 24, 2018

Study Completion Date

February 29, 2020

Conditions
Lung CancerAdenocarcinomaNSCLC
Interventions
DRUG

Crizotinib

250mg crizotinib bid until end of treatment

Trial Locations (18)

13125

Evangelische Lungenklinik Berlin, Berlin

22927

LungenClinic Großhansdorf, Großhansdorf

50937

University of Cologne / LCGC, Cologne

60590

Universitätsklinikum Frankfurt - Medizinische Klinik II, Frankfurt a.M.

69126

Thoraxklinik Heidelberg, Heidelberg

Unknown

Universitätsklinikum Tübingen, Tübingen

Maria Rosaria Garcia Campelo, A Coruña

CEIC Hospital General Universitario de Alicante, Alicante

CEIC Hopsital Vall d'Hebron, Barcelona

Institut Catala D'Oncologia, Barcelona

Hospital Universitario Materno-Infantil de Canarias, Las Palmas de Gran Canaria

CEIC Área 2 - Hospital Universitario de La Princesa, Madrid

CEIC Área 6 - Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda

CEIC Malaga Nordeste - Hospital Regional Universitario Carlos Haya, Málaga

Hospital Son Llatzer, Palma de Mallorca

CEIC Hospital Universitario Virgen del Rocio, Seville

CEIC Hospital Clínico Universitario de Valencia, Valencia

Universitätsspital Basel, Basel

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Spanish Lung Cancer Group

OTHER

collaborator

Pfizer

INDUSTRY

lead

University of Cologne

OTHER

NCT02183870 - EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer | Biotech Hunter | Biotech Hunter